TORONTO -- (MARKET WIRE) -- 02/13/2006 -- Generex Biotechnology Corporation (NASDAQ: GNBT) announced today that on February 10, 2006, Antigen Express, Inc., its wholly owned immunotherapeutics subsidiary, concluded a positive Pre-Investigational New Drug Application (IND) meeting with the U.S. Food and Drug Administration (FDA) regarding plans for the commencement of clinical trials of the proprietary and innovative Antigen Express vaccine to protect against the H5N1 avian influenza.
